financetom
Business
financetom
/
Business
/
BRIEF-Experian Acquires Strategic Stake In Reward
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Experian Acquires Strategic Stake In Reward
May 22, 2024 7:32 AM

May 22 (Reuters) - REWARD:

* EXPERIAN ACQUIRES STRATEGIC STAKE IN REWARD

* REWARD: KASHIF ASLAM APPOINTED TO REWARD BOARD OF

DIRECTORS WITH

IMMEDIATE EFFECT

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hormel Foods Names Paul Kuehneman Interim CFO
Hormel Foods Names Paul Kuehneman Interim CFO
Oct 29, 2025
09:41 AM EDT, 10/29/2025 (MT Newswires) -- Hormel Foods ( HRL ) said Wednesday that Paul Kuehneman has been named interim chief financial officer and controller, effective Oct. 27, succeeding Jacinth Smiley, who is leaving the company. Kuehneman was most recently the company's vice president and controller. Hormel said it will conduct a search for a permanent CFO, which will...
Trailblazer Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing October 31, 2025
Trailblazer Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing October 31, 2025
Oct 29, 2025
New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Trailblazer Acquisition Corp. (the “Company”) announced today that, commencing October 31, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units...
Johnson & Johnson Plans Study Comparing Imaavy With Another FcRn Blocker
Johnson & Johnson Plans Study Comparing Imaavy With Another FcRn Blocker
Oct 29, 2025
09:44 AM EDT, 10/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that it is planning a study comparing Imaavy with efgartigimod, an FcRn blocker, for patients with generalized myasthenia gravis. The phase 3b study will determine whether treatment with Imaavy provides superior disease control versus efgartigimod, and will also include a treatment-switch arm to assess efficacy...
FFW Corp Q3 profit rises on higher margin
FFW Corp Q3 profit rises on higher margin
Oct 29, 2025
Overview * FFW Corp ( FFWC ) Q3 net income rises 22% yr/yr to $1.52 mln * Net interest income for Q3 grows to $4.51 mln from $3.78 mln yr/yr * Company repurchased 729 shares at $40.00 avg price in Q3 Outlook * FFW Corporation ( FFWC ) did not provide specific guidance for future quarters Result Drivers * NET...
Copyright 2023-2026 - www.financetom.com All Rights Reserved